All In Biotech

NDA 022430 · J Molner

Lysteda

Tranexamic Acid · Oral · Antifibrinolytic Agent

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Nov 13, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

175 Phase 3, 72 recruiting

FAERS reports

8,563

7,950 serious, 1,245 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2026.

Tranexamic acid USP tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see Clinical Studies (14) ]. Tranexamic acid USP tablets is an antifibrinolytic indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential. ( 1 )

Mechanism: Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin’s matrix structure. The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for tranexamic acid (K d = 750 μmol/L) and 1 with high...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LYSTEDA · TRANEXAMIC ACID 650MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tranexamic Acid" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective641
  • off label use632
  • pyrexia347
  • hypotension322
  • nausea322
  • diarrhoea308
  • haemorrhage296
  • vomiting290
  • dyspnoea283
  • pneumonia265
  • febrile neutropenia246
  • anaphylactic reaction230

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200533
200639
200731
200865
200962
2010144
2011181
2012164
2013161
2014173
2015263
2016296
2017385
2018445
2019632
2020579
2021806
2022843
2023675
2024917
2025997
2026635

Recalls

2 FDA enforcement reports for this application.

  • Jun 12, 2023 · Class III · Terminated

    Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

  • Jun 13, 2023 · Class III · Ongoing

    Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,180 on PubMed

Sponsor: J Molner

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.